Pharmaceutical high profits: The value of R&D, or oligopolistic rents?

American Journal of Economics and Sociology

Volumn 71, Issue 1, 2012, Pages 1-36

  Spitz, Janet ^a   Wickham, Mark ^a  

^a Lakeview Mental Health Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ARTICLE; DRUG COST; DRUG INDUSTRY; ECONOMICS; EDUCATION; ETHNOLOGY; HEALTH CARE COST; HISTORY; LEGAL ASPECT; RESEARCH; UNITED STATES;

DRUG COSTS; DRUG INDUSTRY; ECONOMICS; HEALTH CARE COSTS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; PHARMACEUTICAL PREPARATIONS; RESEARCH; UNITED STATES;

EID: 84855473325     PISSN: 00029246     EISSN: 15367150     Source Type: Journal    
DOI: 10.1111/j.1536-7150.2011.00820.x     Document Type: Article

References (83)

1. Agovino, T. (2004). "Medicine Price Hike Highlights Controversy of Government Funding Drug Research." Medical Letter on the CDC and FDA, June 20, NewsRx.com and NewsRx.net.
2. American Medical Student Association. (2005). "Marketing Versus Research and Development." Accessed at, March 31.
3. Angell, M. (2005). The Truth About the Drug Compaies. New York: Random House.
4. Armey, Rep. R. K. (1993). "Expressing the Sense of the Congress that Any Federal Health Care Legislation Should Not Include Price Controls." H. Congressional Resolution # 79, introduced 4/2/1993. Accessed at.
5. Avorn, J., M. Chen, and R. Hartley. (1982). "Scientific Versus Commercial Sources of Influence on the Prescribing Behavior of Physicians. American Journal of Medicine 73(1): 4-8.
6. Banks, J., M. Marmot, Z. Oldfield, and J. P. Smith. (2006). "Disease and Disadvantage in the United States and in England." Journal of the American Medical Association 295(17): May 3.
7. Berndt, E., L. Bui, D. Reiley, and G. Urban. (1995). "Information, Marketing and Pricing in the U.S. Antiulcer Drug Market. American Economic Review 85(2): 100-105.
8. Bioresearch Online. (2006). "Average Cost to Develop a New Biotechnology Product is $1.2 Billion." Accessed at.
9. Birn, A. E., and N. Molina. (2005). "In the Name of Public Health." American Journal of Public Health 95(7): 1095-1097.
10. Broder, J. M. (2005). "California Accuses Drug Companies of Fraud." New York Times Aug 25.
11. Castellblanch, R. (2003). "Challenging Pharmaceutical Industry Political Power in Maine and Vermont." Journal of Health Politics, Policy and Law 28(1): Feb.
12. Census, U.S. Bureau. (2008). "Concentration Ratios: 2002." Accessed at.
13. Chandra, A., J. Gruber, and R. McKnight. (2007). "Patient Cost-Sharing, Hospitalization Offsets, and the Design of Optimal Health Insurance for the Elderly." NBER Working Paper 12972.
14. Chen, J., and J. A. Rizzo. (2010). "Who Pays for Drug Quality?" Eastern Economic Journal 36(2): 239-254.
15. Cutler, D. M. (1994). Your Money or Your Life: Strong Medicine for America's Health Care System. New York: Oxford Univ. Press.
16. Cypher, J. M. (2004). "Pinochet Meets Polanyi? The Curious Case of the Chilean Embrace of 'Free' Market Economics. Journal of Economic Issues 38(2): 527-535.
17. Derrida, J. (1996). Monolingualism of the Other. Palo Alto, CA: Stanford Univ. Press, P. Mensah, 1998 translation.
18. DiMasi, J. A., R. W. Hansen, and H. G. Grabowski. (2003). "The Price of Innovation: New Estimates of Drug Development Costs." Journal of Health Economics 22: 151-185.
19. Dor, A., and W. Encinosa. (2004). "Does Cost Sharing Affect Compliance?" NBER Working Paper 10738.
20. Edwards, J. (2009). "Pharma Lobbying Money." Accessed at bnet.com.
21. Elzinga, K. G., and D. E. Mills. (1997). "The Distribution and Pricing of Prescription Drugs." International Journal of the Economics of Business 4(3): 287-298.
22. Epstein, R. (2006). Overdose: How Excessive Government Regulation Stifles Pharmaceutical Innovation. New Haven: Yale Univ. Press.
23. Facchinetti, N. J., and W. M. Dickson. (1982). "Access to Generic Drugs in the 1950s: The Politics of a Social Problem." American Journal of Public Health 72(5): 468-475.
24. Federal Trade Commission (FTC). (2002). "Generic Drug Entry." July.
25. Flyvbjerg, B. (1998). Rationality and Power: Democracy in Practice. Chicago: University of Chicago Press.
26. Freking, K. (2006). "A Grim Prognosis: Staggering Costs of Health Care Await U.S." Albany Times Union, p. A1, February 22.
27. Friedman, M., and R. D. Friedman. (1962). Capitalism and Freedom. Chicago: University of Chicago Press.
28. Gagnon, M. A., and J. Lexchin. (2008). "The Cost of Pushing Pills: A New Estimate of Pharmacetuical Promotion Expenditures in the United States." PLoS Medicine 5(1): e1. Accessed at.
29. GAO. (1992). "Prescription Drugs: Companies Typically Charge More in the United States than in Canada." GAO/HRD-92-85. Washington, DC: U.S. Congress, General Accounting Office, September.
30. Gaynor, M., L. Jian, and W. Vogt. (2006). "Is Drug Coverage a Free Lunch?" NBER Working Paper 12758.
31. Gerth, J., and S. Stolberg. (2000). "Medicine Merchants: Drug Companies Profit from Research Supported by Taxpayers." NY Times, April 23.
32. Goozner, M. (2004). The $800 Million Pill: The Truth Behind the Cost of New Drugs. Berkeley: Univ. of California Press.
33. Grabowski, H. G., and J. M. Vernon. (1987). "Pioneers, Imitators, and Generics." Quarterly Journal of Economics 102(3): 491-525.
34. Grande, D. (2010). "Limiting the Influence of Pharmaceutical Industry Gifts on Physicians: Self-Regulation or Government Intervention?" Accessed at Pubmed.gov.
35. Harris, S. E. (1951). "The British Health Experiment: The First Two Years of the National Health Service." The Economics of Medical Care: II Alternative. American Economic Association.
36. Hayakawa, S. I. (1941). Language in Action. New York: Harcourt, Brace and Co.
37. Hayward, C. R. (2000). De-Facing Power. Cambridge: Cambridge Univ. Press.
38. Hevesi, A. G. (2005). "Budget Review, Erie County June 2005." Office of the NYS Comptroller, Division of Local Government Services & Economic Development, Albany NY, June.
39. Hollon, M. F. (2005). "Direct-to-Consumer Advertising: A Haphazard Approach to Health Promotion." Journal of the American Medical Association 293(16).
40. Hutcheson, R. (2006). "Budget Extends Tax Cuts." Knight-Ridder, p. A1, Albany Times Union Feb 7.
41. Ismail, M. A. (2005). "Drug Lobby Second to None." Center for Public Integrity. Accessed at, July 7.
42. Justice, U.S. Government Dept. of. (2004). "Improving Health Care: A Dose of Competition-Chapter 7 Industry Snapshot and Competition Law: Pharmaceuticals." Accessed at.
43. Kaiser Family Foundation. (2008). "Prescription Drug Trends." September. Accessed at.
44. Kimbuende, E., U. Ranji, J. Lundy, and A. Salganicoff. (2010). "U.S. Health Care Costs: Background Brief." Kaiser Family Foundation. Accessed at.
45. Kotzian, P. (2004). "Pharmaceutical R&D in the Setting of Incomplete European Integration." Int. J. of the Economics of Business 11(2): 175-195.
46. Krueger, L. (2005). "NY State Senate Introducer's Memorandum in Support of S3510." Accessed at.
47. Kusserow, R. P. (2002). "Promotion of Prescription Drugs Through Payments and Gifts." Dept of Health and Human Services, Office of Inspector General. Accessed at.
48. Landry, R. S. (1945). "The Federal Trade Commission and 'Unfair Competition' in Foreign Trade." American Economic Review 35(4): 575-584.
49. Levins, R. (2010). "Why Programs Fail." Monthly Review 61(10): 43-49.
50. Lexchin, J., and B. Mintzes. (2002). "Direct-to-Consumer Advertising of Prescription Drugs: The Evidence Says No." Journal of Public Policy and Marketing 21(2): 194-201.
51. st Ed 1974). London: Palgrave.
52. MacLeod, W. B., G. Norman, and J. F. Thisse. (1987). "Competition, Tacit Collusion and Free Entry." Economic Journal 97(March): 189-198.
53. Marshall, A. (1890). Principles of Economics. Great Britain: Macmillan, 1946 reprint.
54. Masson, R. T., and J. Shaanan. (1984). "Social Costs of Oligopoly and the Value of Competition." Economic Journal 94: 520-535.
55. Matthews, M. Jr. (2001). "Who's Afraid of Pharmaceutical Advertising? A Response to a Changing Health Care System." Lewiston, TX: IPI Center for Technology Freedom Policy Report #155.
56. Murphy, K. M., and R. Topel. (2001). "The Economic Value of Medical Knowledge." University of Chicago. Accessed at March 1998, Revised September.
57. Newhouse, J. P. (1992). "Medical Care Costs: How Much Welfare Loss?" Journal of Economic Perspectives 6(3): 3-21.
58. Nordhaus, W. D. (2002). "The Health of Nations: The Contribution of Improved Health to Living Standards." Cowles Foundation Discussion Paper 1355. Accessed at, February.
59. Odato, J. M. (2006). "Treating Health Costs." Albany Times Union Capital Bureau, January 14.
60. OECD. (2010). "Pharmaceutical Pricing Policy Project." Accessed at.
61. OECD. (2008). "Health Policy Studies: Pharmaceutical Pricing Policies in a Global Market." Accessed at.
62. Olson, M. K. (1995). "The Effects of U.K. Pharmaceutical Policy on Government Drug Expenditures: Cost Control and Incentives for R&D." International Journal of the Economics of Business 2(1): 1995.
63. OTA (Office of Technology Assessment). (1993). "Pharmaceutical R&D: Costs, Risks, and Rewards." OTA-H-522. Accessed at.
64. Pemberton, C. A. (2002). "Influencing the Influencer." Canadian Pharmaceutical Marketing, Fall.
65. Pharmaceutical Research and Manufacturers of America. (2004). Pharmaceutical Industry Profile 2004. Washington, DC: PhRMA.
66. Pharmaceutical Research and Manufacturers of America v. Walsh, Acting Commissioner, Maine Department of Human Services, et al., certiorari to the United States Court of Appeals for the First Circuit. (2003). No. 01-188. Argued January 22, 2003-Decided May 19. Accessed at.
67. Public Citizen. (2003). "2002 Drug Industry Profits: Hefty Pharmaceutical Company Margins Dwarf Other Industries." Accessed at.
68. Robinson, A. R., K. B. Hohmann, J. I. Rifkin, D. Topp, C. M. Gilroy, J. A. Picard, and R. J. Anderson. (2004). "Direct-to-Consumer Pharmaceutical Advertising: Physician and Public Opinion and Potential Effects on the Physician-Patient Relationship." Archives of Internal Medicine 164(4): 427-432.
69. Saul, S. (2005). "Drug Lobby Got a Victory in Trade Pact Vote." NY Times, July 2.
70. Scherer, F. M. (1983). "R&D and Declining Productivity Growth." American Economic Review 73(2): 215-218.
71. rd Edition. Boston: Houghton Mifflin.
72. Sequera, V. (2007). "Brazil Bypasses Patent on U.S. AIDS Drug." Retrieved 5/4 from Associated Press news at.
73. Skinner, J., and W. Zhou. (2005). "The Measurement and Evolution of Health Inequality: Evidence from the U.S. Medicare Population." NBER Working Paper 10842.
74. Spitz, J. (1998). "Human Nature and Judicial Interpretation of Equal Employment Law." Managerial and Decision Economics 19: 521-535.
75. Stigler, G. (1971). "The Theory of Economic Regulation." Bell Journal of Economics and Management Science 2(1): 3-21.
76. Stiglitz, J. (2003). Globalization and Its Discontents. New York: Norton.
77. Strunk, B. C., and P. B. Ginsburg. (2004). "Tracking Health Care Costs: Spending Growth Slowdown Stalls in First Half of 2004." Center for Studying Health System Change Issue Brief No. 91.
78. Watkins, C., L. Moore, I. Harvey, P. Carthy, E. Robinson, and R. Brawn. (2003). "Characteristics of General Practitioners Who Frequently See Drug Industry Representatives: National Cross Sectional Study. BMJ 326: 1178-1179.
79. W.H.O. (2009). "World Health Statistics: Table1-Mortality." Accessed at.
80. Wickham, M. (2006). Personal Observation 1998-2003, in private communication 8/22.
81. Wilkenfeld, J., and J. Braun-Davis. (2005). "50 5 2005: Five Things You Can Do to Prepare for Compliance in All 50 States-Starting Today." Pharmaceutical Executive, Sept. 1. Accessed at.
82. Williamson, O. (1975). Markets and Hierarchies. New York: Free Press.
83. Willis, R. C. (2009). "Patent Pendulum." Drug Discovery News 5(12). Accessed at.